Sichuan Hezong Zehui Pharmaceutical Technology

Sichuan Hezong Zehui Pharmaceutical Technology is a clinical-stage biotechnology company based in Chengdu, China, dedicated to the development of innovative small molecule drugs. The company focuses on addressing unmet medical needs in oncology and metabolic disorders, with a specialized research emphasis on the RAS signaling pathway. Its lead candidate, HZ-A-018, is a KRAS G12C inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. Additionally, the company is advancing HZ-A-029, a potent KRAS G12D inhibitor, alongside other discovery-stage programs targeting key drivers of cancer progression. Hezong Zehui leverages its internal R&D capabilities and strategic location in the Chengdu Tianfu International Bio-town to accelerate its drug discovery efforts. The firm aims to provide effective and affordable therapeutic options for patients globally through rigorous scientific innovation.